Bojimed Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "the Company") hereby announces the report on the dilution of immediate returns from issuing stocks to specific targets in 2026 and the measures to compensate for this dilution and related commitments.
The Company and its board of directors ensure that the information disclosed is true, accurate, and complete, without any false records or misleading statements.
This report is based on the relevant provisions of the China Securities Regulatory Commission and the Shenzhen Stock Exchange regarding the issuance of stocks to specific targets. The Company will further enhance its governance structure and improve the protection of investors' rights and interests.
I. Impact of the Issuance of Stocks to Specific Targets on Major Financial Indicators
The issuance of stocks to specific targets is expected to have the following impacts on the Company's major financial indicators:
-
Assuming the economic environment remains stable, the Company's industry policies, business development status, and market conditions do not change significantly;
-
The issuance of stocks to specific targets will be implemented in November 2026, and this period will be used to analyze the impact of the issuance on major financial indicators, without considering the changes in the Company's overall financial situation;